Medprime launches Micalys, AI-integrated digital microscopy platform

New Delhi: Medprime Technologies has introduced Micalys, an unprecedented AI-integrated digital microscopy platform aimed at revolutionizing digital pathology in India.

Founded by biomedical engineering postgraduates from IIT Bombay in 2014, Medprime has garnered substantial support from the USAID-backed SAMRIDH fund, managed by IPE Global, along with as well as BIG and SBIRI grants from BIRAC. The company’s strategic alliances include partnerships with academic institutions like IIT Bombay, incubators such as SINE and Venture Centre, and collaborations with industry bodies like NASSCOM. Further bolstered by investments from prominent venture capital firms like Lavni Ventures and Riso Capital, Medprime has focused on pushing the boundaries of diagnostic technology, with Micalys being its latest breakthrough.

Micalys represents a multifunctional microscopy platform equipped with advanced features poised to become indispensable in diagnostic labs, research facilities, and educational institutions nationwide. Key features include whole slide imaging, live view with remote robotic control, traditional manual microscopy capabilities, and AI-assisted diagnosis for various histological and cytological samples. Notably, Micalys supports up to 100x magnification, including unique 100X oil immersion imaging, facilitating telepathology applications for the precise detection of parasites, infections, and blood abnormalities.

The platform features a user-friendly interface with an intuitive design for ease of use across all skill levels. It offers exceptional speed and resolution, comparable or superior to leading branded scanners, at a globally unmatched price point for single-slide WSI systems. This affordability ensures equitable access to advanced diagnostic technology for labs of all sizes.

Samrat Singh, Founder and CEO of Medprime Technologies, emphasized, “At Medprime, our mission has always been to provide cutting-edge health solutions with affordable pricing and with Micalys, we have achieved a breakthrough by integrating cutting-edge AI and digital imaging technologies into a microscope that elevates diagnostic precision, streamlines workflows, and boosts overall productivity. This innovation addresses the critical challenges of accessibility and timeliness in healthcare diagnosis especially in remote India where the bottom 40% of the population is located. Micalys is also addressing the element of affordability for smaller labs, diagnostic centers and hospitals to ensure quality healthcare across the country.”

The scarcity of pathologists globally, compounded by increasing patient numbers, has strained healthcare systems. Micalys addresses these challenges by eliminating the need for physical sample transport to centralized facilities, enabling remote diagnosis by pathologists anywhere globally. This capability ensures timely access to expert opinions, regardless of geographic location.

Furthermore, Micalys holds promise for screening diseases like malaria, filaria, and tuberculosis in resource-limited areas, leveraging AI-driven analysis to bridge gaps in diagnostic capabilities where trained technicians are scarce. The platform allows for enhanced precision in diagnosing a spectrum of conditions, digital record-keeping and rapid data access, facilitating informed decision-making by health authorities.

Medprime’s commitment to innovation is underscored by its robust intellectual property portfolio, including recently granted patents from the Government of India. Already embraced by prestigious institutions such as AIIMS, Maulana Azad Medical College, Grant Medical College, Banaras Hindu University, IIT Delhi, IIT Madras, Dr Lal Path Labs, Apollo Diagnostics and Dr. Rajendra Prasad Central Agricultural University, Micalys exemplifies Medprime’s dedication to advancing healthcare through cutting-edge technology.